Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Drug Name | MORAb-202 |
| Trade Name | |
| Synonyms | MORAb 202|MORAb202 |
| Drug Descriptions |
MORAb-202 is an anti-folate receptor alpha (FRA) antibody (farletuzumab) in conjugation with eribulin, which may lead to cytotoxic killing of FRA-positive tumors (Mol Cancer Ther 2018;17(1 Suppl):Abstract nr B115, PMID: 30262588). |
| DrugClasses | FOLR1-targeted Therapy 24 |
| CAS Registry Number | NA |
| NCIT ID | C173946 |
| Therapy Name | Drugs | Efficacy Evidence | Clinical Trials |
|---|---|---|---|
| Dexamethasone + MORAb-202 | Dexamethasone MORAb-202 | 0 | 1 |
| Lenvatinib + MORAb-202 | Lenvatinib MORAb-202 | 0 | 1 |
| MORAb-202 | MORAb-202 | 0 | 3 |
| MORAb-202 + Prednisolone | MORAb-202 Prednisolone | 0 | 1 |
| MORAb-202 + Prednisone | MORAb-202 Prednisone | 0 | 1 |